Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity

Clin Cancer Res. 2020 Jun 1;26(11):2439-2440. doi: 10.1158/1078-0432.CCR-20-0707. Epub 2020 Mar 31.

Abstract

PARP inhibitors (PARPi) are promising in BRCA2-altered prostate cancer. Data were presented on PARPi efficacy in prostate cancers with alterations in other DNA damage repair genes which suggest low response rates in ATM-, CHEK2-, CDK12-altered tumors and promising results in PALB2-, RAD51B-, FANCA-, and BRIP1-altered tumors.See related article by Abida et al., p. 2487.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • DNA Damage
  • Humans
  • Indoles
  • Male
  • Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
  • Prostatic Neoplasms, Castration-Resistant*

Substances

  • Indoles
  • Poly(ADP-ribose) Polymerase Inhibitors
  • rucaparib